BioNxt Solutions Inc. (FRA:BXT)
0.4110
-0.0060 (-1.44%)
Last updated: Dec 5, 2025, 11:28 AM CET
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 11.26K CAD in the quarter ending September 30, 2025, a decrease of -34.17%. This brings the company's revenue in the last twelve months to 15.82K, down -62.34% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
15.82K CAD
Revenue Growth
-62.34%
P/S Ratio
5,461.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
52.87M EUR
Revenue Chart
* This company reports financials in CAD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Rheinmetall AG | 11.00B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
BioNxt Solutions News
- 5 days ago - BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments - Wallstreet:Online
- 16 days ago - BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform - Wallstreet:Online
- 4 weeks ago - BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies - Wallstreet:Online
- 5 weeks ago - BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization - Wallstreet:Online
- 6 weeks ago - BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study - Wallstreet:Online
- 2 months ago - BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities - Wallstreet:Online
- 2 months ago - BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis - Wallstreet:Online
- 2 months ago - BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform - Wallstreet:Online